10-Q: Apogee Therapeutics Reports Q3 2025 Results, Advances Pipeline

Apogee Therapeutics reports increased net loss in Q3 2025 but highlights positive clinical data for APG777 and significant capital raise post-quarter end.

Summary

• Net loss for the three months ended September 30, 2025, was $65.0 million, compared to $49.0 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $186.5 million, compared to $114.9 million for the same period in 2024.
• Research and development expenses increased by $8.5 million to $54.2 million for Q3 2025, primarily due to further development of the APG777 program and increased personnel costs.
• General and administrative expenses increased by $4.1 million to $17.1 million for Q3 2025, driven by increased headcount and equity-based compensation.
• As of September 30, 2025, cash and cash equivalents, marketable securities, and long-term marketable securities totaled $588.9 million.
• Post-quarter end, on October 10, 2025, the company closed an underwritten public offering, raising approximately $324.1 million in net proceeds.
• The APG777 Phase 2 APEX trial in moderate-to-severe Atopic Dermatitis (AD) met its primary endpoint, showing a 71.0% Eczema Area Severity Index (EASI) reduction from baseline at Week 16, compared to 33.8% for placebo (p < 0.001).
• 66.9% of APG777-treated participants achieved EASI-75 compared to 24.6% on placebo (p < 0.001), noted as the highest absolute and placebo-adjusted EASI-75 of any biologic in a 16-week global study.
• APG777 demonstrated a potential best-in-class pharmacokinetic (PK) profile with a half-life of 77 days, supporting potential for every threeto six-month maintenance dosing in AD.
• Positive interim safety and PK data were reported for APG990 (anti-OX40L antibody) with a half-life of approximately 60 days, and APG333 (anti-TSLP antibody) with a half-life of approximately 55 days.
• APG808 (anti-IL4R antibody) Phase 1b trial in mild-to-moderate asthma showed rapid and sustained FeNO suppression (53% maximal decrease, 50% sustained at 12 weeks) and a half-life of approximately 55 days, supporting 2-month or longer maintenance dosing.

Sentiment

Score: 7

Explanation: The company reported increased net losses but delivered strong positive clinical trial data for its lead candidate APG777, which significantly de-risks the program. A substantial capital raise post-quarter end also provides a long cash runway, offsetting the increased burn rate. The delay in some Phase 2b trials is a minor negative against the strong clinical progress.

Positives

• APG777 Phase 2 APEX trial in AD met its primary endpoint with a statistically significant EASI reduction of 71.0% compared to placebo's 33.8% (p < 0.001).
• APG777 achieved 66.9% EASI-75, noted as the highest absolute and placebo-adjusted EASI-75 of any biologic in a 16-week global study.
• APG777 demonstrated a potential best-in-class PK profile with a 77-day half-life, supporting potential for every threeto six-month maintenance dosing.
• APG808 showed rapid and sustained FeNO suppression in asthma patients, reinforcing potential for 2-month or longer maintenance dosing, a significant advantage compared to current bi-weekly standard of care.
• Positive interim safety and PK data were reported for APG990 (60-day half-life) and APG333 (55-day half-life), indicating favorable dosing potential.
• Successful completion of a $324.1 million public offering in October 2025, significantly extending the cash runway into the second half of 2028.
• Advancement of multiple pipeline candidates (APG777, APG990, APG333, APG808) into or through clinical trials, demonstrating pipeline progress.
• Preclinical studies for APG279 (APG777 + APG990) demonstrated broad inhibition of Type 1, Type 2, and Type 3 inflammation, similar to JAK inhibition but with potential for better tolerability.

Negatives

• Net loss increased to $65.0 million for Q3 2025 from $49.0 million in Q3 2024, and to $186.5 million for the nine months ended September 30, 2025, from $114.9 million in 2024.
• Accumulated deficit reached $492.4 million as of September 30, 2025, reflecting significant historical losses.
• Negative cash flows from operations totaled $164.8 million for the nine months ended September 30, 2025.
• Interest income decreased by $3.4 million for Q3 2025 and $4.8 million for the nine months ended September 30, 2025, compared to prior year periods.
• The previously communicated initiation of APG777 Phase 2b clinical trials in asthma and EoE will be delayed as trial designs will be informed by ongoing studies.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate current business and likelihood of success.
• Requires substantial additional capital to finance future operations; inability to raise capital could force delays or elimination of development programs.
• Expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability.
• Faces competition from entities that have developed or may develop programs for the diseases addressed by its product candidates.
• Programs are in clinical and preclinical stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.
• Substantially dependent on the success of its product candidates (APG777, APG279, APG273, APG990, APG333, APG808) and ongoing/anticipated clinical trials.
• Approach to discovery and development of programs is unproven, and efforts to build a pipeline with commercial value may not be successful.
• Preclinical and clinical development is a lengthy, expensive, and uncertain process with outcomes that may not be predicted by earlier studies.
• Difficulties enrolling patients in current and future clinical trials could delay or adversely affect clinical development activities.
• Preliminary, topline, or interim data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Current and future clinical trials may reveal significant adverse events or undesirable side effects not seen in preclinical studies.
• May expend limited resources to pursue a particular program and fail to capitalize on more profitable opportunities.
• Any approved products may not achieve adequate market acceptance among clinicians, patients, healthcare payors, and others.
• Certain programs may compete with other company programs, potentially reducing future revenue.
• Conducting clinical trials outside the United States carries risks, and the FDA may not accept data from such locations.
• Relies on collaborations and licensing arrangements with third parties (e.g., Paragon), and their failure could negatively impact the business.
• Relies on third parties to conduct and support preclinical studies and clinical trials; failure to perform could delay regulatory approval.
• Reliance on foreign Contract Manufacturing Organizations (CMOs) exposes the company to supply chain disruption, delays, regulatory risks, and increased costs.
• May experience difficulties in managing growth as the organization expands.
• Highly dependent on key personnel and may have difficulty attracting and retaining highly qualified personnel.
• Operating in foreign markets subjects the company to additional regulatory burdens and risks.
• Employees, independent contractors, and other collaborators may engage in misconduct or improper activities.
• Internal information technology systems or those of third parties may fail or suffer security or data privacy breaches.
• Subject to stringent and changing laws, regulations, and standards relating to privacy, data protection, and data security.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• May be subject to adverse legislative or regulatory tax changes.
• Acquisitions or strategic alliances may not realize expected benefits.
• Maintains cash at financial institutions in balances exceeding federally-insured limits, exposing to potential loss.
• Ability to protect patents and other proprietary rights is uncertain, risking loss of competitive advantage.
• May be subject to patent infringement claims or need to file claims to protect intellectual property, resulting in substantial costs and liability.
• Changes to patent laws in the United States and other jurisdictions could diminish the value of patents.
• May not identify relevant third-party patents or incorrectly interpret their relevance, scope, or expiration.
• May become subject to claims challenging the inventorship or ownership of patents and other intellectual property.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Technology licensed from various third parties may be subject to retained rights.
• Regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Disruptions at the FDA and other government agencies could negatively affect the review and approval of regulatory submissions.
• May not be able to meet requirements for the chemistry, manufacturing, and control of product candidates.
• Programs intended for approval as biologics may face competition sooner than anticipated due to biosimilars.
• Subject to extensive ongoing regulatory obligations and continued regulatory review post-approval.
• May face difficulties from healthcare legislative reform measures.
• Business operations and arrangements with healthcare professionals are subject to applicable healthcare regulatory laws, exposing to penalties.
• Potential unfavorable pricing regulations and/or third-party coverage/access and reimbursement policies may harm the business.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws.
• Governments outside the United States tend to impose strict price controls.
• Seeking Fast Track Designation by the FDA may not lead to a faster development or regulatory review/approval process.
• Quarterly and annual operating results may fluctuate significantly or fall below expectations, causing stock price volatility.
• The price of the stock has fluctuated and may continue to be volatile.
• Principal stockholders and management own a significant percentage of stock and can exert significant influence.
• A sale of a substantial number of shares may cause the market price to drop significantly.
• Provisions in corporate documents and Delaware law might discourage, delay, or prevent a change in control.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum.
• Does not anticipate paying dividends, so capital appreciation is the sole source of gain.
• Estimates of market opportunity and forecasts of market growth may prove inaccurate.
• Dual class structure of common stock may limit influence.
• May become exposed to costly and damaging liability claims.
• Litigation costs and outcomes could have a material adverse effect.
• If securities or industry analysts do not publish research or publish adverse reports, stock price and trading volume could decline.
• Will continue to incur increased costs as a public company, and management will devote substantial time to compliance.
• Failure to maintain proper and effective internal controls over financial reporting could impair ability to produce accurate financial statements.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions.

Future Outlook

The company expects to continue incurring significantly increased expenses as it advances its programs (APG777, APG279, APG273, APG990, APG333, APG808) through clinical trials and regulatory approval. It plans to initiate a Phase 3 trial for APG777 in AD in the second half of 2026 and announce plans for Phase 2b trials in asthma and EoE in 2026. Topline maintenance data from APG777 Part A is anticipated in Q1 2026, with 16-week topline induction data from Part B expected in Q2 2026. The company estimates that its existing cash, cash equivalents, marketable securities, and the $324.1 million net proceeds from the October 2025 Offering will be sufficient to fund operating expenses and capital requirements into the second half of 2028.

Management Comments

• We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets.
• We believe each of our programs has potential for broad application across multiple I&I indications.
• Based on our clinical data, we expect to further evaluate additional opportunities to develop APG777 for other I&I indications, including alopecia areata, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria, and prurigo nodularis.
• We plan to evaluate APG777 in combination with other investigational therapies within our pipeline to potentially enable greater efficacy for I&I conditions.
• We expect that our cash and cash equivalents of $107.9 million, marketable securities of $419.4 million and long-term marketable securities of $61.6 million as of September 30, 2025, in addition to the $324.1 million in net proceeds from the October 2025 Offering, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028.

Industry Context

Apogee Therapeutics operates in the highly competitive inflammatory and immunology (I&I) market, focusing on conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis. The company's strategy involves developing novel biologics with optimized half-lives to potentially offer differentiated efficacy and dosing compared to existing standard-of-care therapies like DUPIXENT and EBGLYSS. The development of combination therapies, such as APG279, aims to achieve broader inflammation inhibition, potentially offering better tolerability than current Janus kinase (JAK) inhibitors. The biotechnology industry faces significant challenges including high research and development costs, lengthy and unpredictable regulatory approval processes, and intense competition for patient enrollment in clinical trials and market share. Macroeconomic conditions and geopolitical events also pose ongoing risks to supply chains and capital availability within the sector.

Comparison to Industry Standards

• APG777's 71.0% EASI reduction at Week 16 compares favorably to standard of care biologics in non-head-to-head trials for moderate-to-severe AD.
• APG777's 66.9% EASI-75 achievement is noted as the highest absolute and placebo-adjusted EASI-75 of any biologic in a 16-week global study.
• APG777's half-life of 77 days supports potential for every threeto six-month maintenance dosing, offering a significant advantage over current bi-weekly standard of care (e.g., DUPIXENT, which is bi-weekly).
• APG808's optimized PK profile and FeNO suppression out to 12 weeks reinforces potential for 2-month or longer maintenance dosing, a significant advantage compared to current bi-weekly standard of care (e.g., DUPIXENT).
• APG990's half-life of approximately 60 days and APG333's half-life of approximately 55 days also suggest less frequent dosing compared to many existing biologics.
• APG333's depth of suppression in key biomarkers (eosinophils, IL-5) is in line with TSLP analogs (e.g., TEZPIRE).
• APG279 (APG777 + APG990) preclinical studies demonstrated broad inhibition of Type 1, Type 2, and Type 3 inflammation, similar to Janus kinase (JAK) inhibition but with potential for better tolerability than JAK inhibitors.

Related Party Transactions

• Paragon Therapeutics, Inc. is considered a related party, with a stockholder beneficially owning more than 5% of both companies and having two seats on the Board of Directors.
• The company incurred $0.1 million in research and development expenses with Paragon for services under Option and License Agreements for the nine months ended September 30, 2025, a decrease from $11.1 million in the same period of 2024.
• Milestone payments were made to Paragon: $1.0 million for IL-4R development candidate (November 2023), $2.0 million for APG808 Phase 1 dosing (March 2024), $1.0 million for OX40L development candidate (May 2024), $2.0 million for APG990 Phase 1 dosing (August 2024), $3.0 million for TSLP development candidate (October 2024), and $5.0 million for APG333 Phase 1 dosing (December 2024).
• The company is obligated to pay low-single digit percentage royalties to Paragon on net sales of any products under the respective License Agreements, once commercialized.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from successful pipeline development and commercialization, but also subject to dilution from capital raises and stock price volatility. Principal stockholders and management exert significant influence over corporate matters.
• Employees: Increased headcount and equity-based compensation reflect growth, but the company faces risks in attracting and retaining key personnel.
• Patients: Potential for new, optimized biologic therapies with differentiated efficacy and dosing for inflammatory and immunology conditions with high unmet needs.
• Third-party manufacturers and CROs: Continued reliance on these partners for research, development, and manufacturing activities, subject to contractual obligations and performance risks.
• Creditors: No significant debt mentioned, but future debt financing could introduce covenants and restrictions.

Next Steps

• Complete enrollment in the Part B portion of the APEX Phase 2 trial by the end of 2025.
• Anticipate topline maintenance data from Part A of the APEX trial in Q1 2026.
• Anticipate topline results from the APG777 Phase 1b asthma trial in Q1 2026.
• Anticipate 16-week topline induction data from the Part B portion of the APEX Phase 2 trial in Q2 2026.
• Anticipate initiation of a Phase 3 trial in AD in the second half of 2026.
• Expect to announce plans for Phase 2b trials in asthma and EoE in 2026.
• Expect a data readout from the Phase 1b trial of APG279 in the second half of 2026.
• Further evaluate additional opportunities to develop APG777 for other I&I indications, including alopecia areata, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria, and prurigo nodularis, in 2027 and beyond.
• Evaluate APG777 in combination with other investigational therapies within the pipeline.
• Advance the development of APG279 in future studies as a coformulation.

Key Dates

Recommendation

The company has demonstrated promising clinical results for its lead candidate APG777 in atopic dermatitis, with data comparing favorably to existing treatments and a potentially best-in-class dosing profile. The recent $324.1 million capital raise significantly strengthens the balance sheet, extending the cash runway into the second half of 2028, which is crucial for a clinical-stage biotech. However, the company continues to incur substantial operating losses, and all programs are still in early to mid-stage development, facing inherent risks of clinical failure, regulatory hurdles, and intense competition. While the clinical progress is encouraging, the stock has likely already priced in much of this positive news. Investors should hold to monitor further clinical trial readouts, progress towards commercialization, and continued financial management.

Keywords

Biotechnology, Clinical-stage, Atopic Dermatitis, Asthma, Eosinophilic Esophagitis, COPD, Inflammatory and Immunology, Monoclonal Antibody, IL-13, OX40L, TSLP, IL-4R, APG777, APG990, APG333, APG808, APG279, APG273, Clinical Trials, Phase 2, Phase 1, PK data, PD data, Biologics, Drug Development, Pharmaceutical, Nasdaq